Pages that link to "Q43942580"
Jump to navigation
Jump to search
The following pages link to Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. (Q43942580):
Displaying 50 items.
- Phosphodiesterase 5 inhibitors for pulmonary hypertension (Q24245844) (← links)
- Prostacyclin for pulmonary hypertension in adults (Q24246933) (← links)
- Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report (Q24813821) (← links)
- Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors (Q24815216) (← links)
- Adenosine-associated delivery systems (Q26785351) (← links)
- Chronic thromboembolic pulmonary hypertension associated with endomyocardial fibrosis of the right ventricle (Q29354029) (← links)
- Inhaled iloprost in pulmonary arterial hypertension (Q30437211) (← links)
- Sildenafil for pulmonary hypertension (Q33213984) (← links)
- Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep (Q33806234) (← links)
- Hua Fo tablets tainted with sildenafil-like compound. (Q33833316) (← links)
- Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies (Q33849207) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension (Q33965898) (← links)
- Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates (Q33965904) (← links)
- Reversal of experimental pulmonary hypertension by PDGF inhibition (Q34048479) (← links)
- Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study (Q34508862) (← links)
- Prostacyclin for pulmonary hypertension (Q34758143) (← links)
- New perspectives for the treatment of pulmonary hypertension (Q34903204) (← links)
- Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease (Q34990647) (← links)
- Treprostinil therapy for pulmonary artery hypertension (Q35001030) (← links)
- Treatment of scleroderma: an update (Q35073374) (← links)
- Phosphodiesterase type 5 (PDE5) inhibitors (Q35140096) (← links)
- The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases (Q35156618) (← links)
- Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma (Q35169057) (← links)
- Intraoperative device closure of atrial septal defects in the older population (Q35364896) (← links)
- A Novel Mechanism for Pulmonary Arterial Hypertension? (Q35540855) (← links)
- Evaluation and management of pulmonary hypertension in systemic sclerosis (Q35564258) (← links)
- Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review (Q35584277) (← links)
- Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension (Q35665744) (← links)
- Nitric oxide and other novel therapies for pulmonary hypertension (Q35750204) (← links)
- Phosphodiesterase inhibitors in the management of primary pulmonary hypertension (Q35767469) (← links)
- Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase (Q35772984) (← links)
- Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. (Q35890965) (← links)
- Sildenafil in the treatment of pulmonary hypertension (Q36013070) (← links)
- When cure is care: diagnosis and management of pulmonary arterial hypertension (Q36062149) (← links)
- Iloprost for idiopathic pulmonary arterial hypertension (Q36107191) (← links)
- Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine (Q36107232) (← links)
- Methylthioninium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass (Q36140718) (← links)
- Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety (Q36150572) (← links)
- Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension (Q36159287) (← links)
- Drug treatment of pulmonary arterial hypertension: current and future agents (Q36174526) (← links)
- Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension (Q36225802) (← links)
- Current treatment strategies for pulmonary arterial hypertension (Q36237720) (← links)
- Combination drug therapy in the management of pulmonary arterial hypertension (Q36308694) (← links)
- Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction (Q36314042) (← links)
- Pulmonary arterial hypertension: new insights and new hope (Q36372605) (← links)
- Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years (Q36408727) (← links)
- Advances in the medical treatment of pulmonary hypertension (Q36420236) (← links)
- Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. (Q36523256) (← links)
- Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. (Q36554423) (← links)
- Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan (Q36570843) (← links)